- Molecular NameMoexipril
- SynonymMoexipril HCl; Moexipril hydrochloride; Moexiprilum [INN-Latin]
- Weight498.576
- Drugbank_IDDB00691
- ACS_NO103775-10-6
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.78
- pka3.05 (25oC); 5.40 (25oC).
- LogD (pH=7, predicted)-1.62
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)-3.71
- LogSw (predicted, AB/LogsW2.0)0.28
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors2
- No.of HBond Acceptors9
- No.of Rotatable Bonds12
- TPSA114.4
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn ACE inhibitor.
- Absorption_valueN/A
- Absorption (description)Moexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food
- Caco_2N/A
- Bioavailability13.0
- Protein binding50.0
- Volume of distribution (VD)183 L (moexipril and moexiprilat).
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmRapidly converted to moexiprilat, the active metabolite. Conversion to the active metabolite is thought to require carboxyesterases and is likely to occur in organs or tissues, other than the gastrointestinal tract, in which carboxyesterases occur. The liver is thought to be one site of conversion, but not the primary site.
- Half life1 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityHuman overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted.
- LD50 (rat)N/A
- LD50 (mouse)N/A